Abstract
Background Since its inception in 2005, the President’s Malaria Initiative (PMI) has played a major role in the reductions in malaria morbidity and mortality witnessed across Africa. With the status of PMI funding and operations currently uncertain, this study aimed to quantify the impact that a fully-functioning PMI would have on malaria cases and deaths in Africa during 2025.
Methods We combined detailed spatio-temporal information on planned 2025 PMI and non-PMI malaria commodity procurement and distribution in Africa with spatio-temporal Bayesian models of intervention coverage and Plasmodium falciparum transmission and burden in Africa. By comparing coverage scenarios with and without planned PMI contributions we estimated the number of malaria cases and deaths PMI would avert in 2025.
Findings We estimated that business-as-usual PMI contributions to vector control, seasonal chemoprevention, and routine malaria treatment in Africa would avert in 2025 14·9M (95% uncertainty interval 12·5M – 17·8M) malaria cases and 107,000 (71,000 – 166,000) deaths. This represents 12·6% (11·1 – 14·2%) and 39·0% (37·1 – 40·4%), respectively, of the total burden of malaria morbidity and mortality in PMI’s focus geographies across 27 African countries. These estimates do not account for the additional impact of PMI-supported provision of diagnostics or severe case management commodities, nor preventive treatment for pregnant women which would add further to the averted burden.
Interpretation PMI investment in supporting procurement and distribution of malaria control commodities would translate directly into millions of malaria cases averted and a hundred thousand lives saved across its focus geographies in Africa across 2025.
Funding National Health and Medical Research Council, Australia
Evidence before this study We searched PubMed on 25 February 2025 with the search term “President’s Malaria Initiative” AND (impact OR evaluation) AND (burden OR malaria cases OR malaria deaths). 102 results were returned, of which four directly addressed the question of PMI-attributable impact on malaria burden across all its focus geographies. One focussed solely on case-management and did not provide quantitative results1. A study focussing on mortality found a strong association between PMI investment and declines in all-cause infant mortality2. Another study used a generalised estimating equation approach to assess PMI’s impact, concluding a strong association between PMI spending and reductions in malaria burden3. A 2017 study used a mechanistic malaria model to estimate PMI’s historic contribution to reductions in malaria morbidity and mortality, with future projections to 20204.
Added value of this study In this study we synthesised the most up-to-date information of all-funder volumes of key malaria control interventions (ITN, IRS, ACT, SMC) with PMI data on planned volumes and spatial targeting of funding in 2025 to derive near-real-time projections of malaria control intervention coverage in Africa under two scenarios: a business-as-usual scenario in which PMI commodities procured and distributed as previously planned versus a ‘no-PMI’ scenario in which PMI funding and technical assistance is absent. These scenario-based estimates of coverage were propagated through an empirical geospatial malaria model, coupled to mechanistic models of clinical incidence, in order to estimate the number of malaria infections, clinical cases, and deaths PMI activities could expect to avert in Africa in 2025.
Implications of all available evidence PMI is a key contributor to malaria control efforts in Africa, and as such its impact on averting childhood mortality has been demonstrated repeatedly. Here, using empirically-derived estimates of malaria control impact, combined with detailed scenarios of intervention coverage with- and without-PMI support, we isolated the contemporary impact of PMI activities on malaria morbidity and mortality in Africa in 2025. Our findings suggest that PMI support is critical to maintaining suppression of malaria transmission in its focus geographies.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work is supported by the National Health and Medical Research Council, Australia (2025280).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos